Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 4922-4932

  Milano, Michael T ^a   Haraf, Daniel J ^a   Stenson, Kerstin M ^a   Witt, Mary Ellyn ^a   Eng, Cathy ^b   Mittal, Bharat B ^c   Argiris, Athanassios ^c   Pelzer, Harold ^d   Kozloff, Mark F ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPIRATION PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEAD CANCER; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NECK CANCER; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMEMBRANOUS COLITIS; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; SKIN INFECTION; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PROGNOSIS; RADIOMETRY; TIME FACTORS; TREATMENT OUTCOME;

EID: 4143083772     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0634     Document Type: Article

References (50)

1. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
2. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-24.
3. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804.
4. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-7.
5. Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer (Phila) 2000;88:876-83.
6. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-64.
7. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst (Bethesda) 1999;91:2081-6.
8. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
9. Adelstein DJ, Li Y, Adams GL, et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
10. Haraf DJ, Vokes EE, Panje WR, Weichselbaum RR. Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol 1991;14:419-26.
11. Haraf DJ, Vokes EE, Weichselbaum RR, Panje WR. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope 1992;102:630-6.
12. Vokes EE, Panje WR, Schilsky RL, et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol 1989;7:761-8.
13. Vokes EE, Haraf DJ, Mick R, McEvilly JM, Weichselbaum RR. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 1994;12:2351-9.
14. Vokes EE, Kies M, Haraf DJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol 1995;13:876-83.
15. Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652-61.
16. Kies MS, Haraf DJ, Athanasiadis I, et al. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol 1998;16:2715-21.
17. Mantz CA, Vokes EE, Stenson K, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J 2001;7:140-8.
18. Mantz CA, Vokes EE, Kies MS, et al. Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. Ann Oncol 2001;12:343-7.
19. Oh JL, Vokes EE, Kies MS, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 2003;14:564-9.
20. Brockstein B, Haraf DJ, Stenson K, et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 1998;16:735-44.
21. Brockstein B, Haraf DJ, Stenson K, et al. A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann Oncol 2000;11:721-8.
22. Kies MS, Haraf DJ, Rosen F, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001;19:1961-9.
23. Rosen FR, Haraf DJ, Kies MS, et al. Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 2003;9:1689-97.
24. Haraf DJ, Weichselbaum RR, Vokes EE. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol 1996;7:913-8.
25. Kao J, Garofalo MC, Milano MT, Chmura SJ, Citron JR, Haraf DJ. Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review. Cancer Treat Rev 2003;29:21-30.
26. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-31.
27. Braakhuis BJ, van Dongen GA, Vermorken JB, Snow GB. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. Cancer Res 1991;51:211-4.
28. Catimel G, Vermorken JB, Clavel M, et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group Ann Oncol 1994;5:543-7.
29. Shewach DS, Lawrence TS. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 1996;23:65-71.
30. Lawrence TS, Eisbruch A, McGinn CJ, Fields MT, Shewach DS. Radiosensitization by gemcitabine. Oncology (Huntingt) 1999;13:55-60.
31. Rosier JF, Beauduin M, Bruniaux M, et al. The effect of 2′-2′ difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity. Int J Radiat Biol 1999;75:245-51.
32. Rosier JF, Michaux L, Ameye G, et al. The radioenhancement of two human head and neck squamous cell carcinomas by 2′-2′ difluorodeoxycytidine (gemcitabine; dFdC) is mediated by an increase in radiation-induced residual chromosome aberrations but not residual DNA DSBs. Mutat Res 2003;527:15-26.
33. Mose S, Karapetian M, Juling-Pohlit L, et al. Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. Anticancer Res 2000;20:401-5.
34. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst (Bethesda) 1996;88:1193-203.
35. Van Laethem JL, Demols A, Gay F, et al. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiat Oncol Biol Phys 2003;56:974-80.
36. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17:2208-12.
37. Crane C, Janjan N, Evans D, et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Gastrointest Cancer 2001;29:9-18.
38. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202-8.
39. Mohiuddin M, Kudrimoti M, Regine WF, McGrath PC, Hanna N, John W. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study. Cancer J 2002;8:255-62.
40. Talamonti MS, Catalano PJ, Vaughn DJ, et al. Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 2000;18:3384-9.
41. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001;7:2246-53.
42. Martenson JA, Vigliotti AP, Pitot HC, et al. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;55:1305-10.
43. Blackstock AW, Lesser GJ, Fletcher-Steede J, et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;51:1281-9.
44. Van Putten JW, Price A, Van Der Leest AH, Gregor A, Little FA, Groen HJ. A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 2003;9:2472-7.
45. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-8.
46. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer (Phila) 2003;97:2791-7.
47. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003;21:320-6.
48. Haraf D, Rosen F, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 2003;9:5936-43.
49. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001;19:792-9.
50. Milano MT, Vokes EE, Witt ME, et al. Retrospective comparison of intensity modulated radiation therapy (IMRT) and conventional three-dimensional RT (3DCRT) in advanced head and neck patients treated with definitive chemoradiation [Abstract]. Proc Am Soc Clin Oncol 2003;22:499.